VYGR Receives FDA Clearance for VY1706 IND, Plans Phase 1 Trial for Alzheimer's Gene Therapy
Voyager Therapeutics, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $3.79
+1.8% in 1h after detection
Post-detection moves
1h
+1.8%
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS